Animal Antithrombin Activity Testing: Principles, Methods, and Laboratory Applications

Animal antithrombin activity testing is a specialized laboratory procedure used to quantify the functional capacity of antithrombin, the principal physiological inhibitor of thrombin and Factor Xa, in animal plasma. This testing plays a critical role in veterinary diagnostics, thrombosis risk assessment, heparin therapy monitoring, and preclinical research. This article provides a comprehensive technical overview of sample requirements, testing items, analytical methods, quality standards, and practical applications of antithrombin activity determination in animal species.

Technical Overview

Antithrombin (AT), formerly known as antithrombin III, is a single-chain glycoprotein belonging to the serine protease inhibitor (serpin) superfamily, with a molecular weight of approximately 58 kDa. It is synthesized primarily in the liver and endothelial cells and circulates in plasma as the most important natural regulator of coagulation. Antithrombin irreversibly inhibits several activated coagulation factors, most notably thrombin (Factor IIa) and Factor Xa, and to a lesser extent Factors IXa, XIa, XIIa, and plasmin. The inhibitory capacity of antithrombin is accelerated approximately 1,000-fold upon binding to heparin or endothelial heparan sulfate, which is the pharmacological basis of heparin anticoagulant therapy.

In healthy domestic animals, antithrombin activity typically falls within a reference interval of approximately 80% to 130% of a pooled species-specific reference plasma. Reduced antithrombin activity below approximately 60% is clinically significant and is associated with hypercoagulable states, most notably disseminated intravascular coagulation (DIC), hepatic insufficiency, protein-losing nephropathy, protein-losing enteropathy, sepsis, and marked inflammation. Because functional antithrombin is a prerequisite for effective heparin therapy, measuring activity is also essential when heparin resistance is suspected in veterinary patients.

Animal antithrombin activity testing is performed by accredited third-party laboratories, veterinary diagnostic laboratories, and research institutions using validated chromogenic, immunological, or clot-based analytical platforms. Test development and reporting are typically conducted under quality management frameworks aligned with ISO/IEC 17025, and assay calibration commonly references WHO International Standards for antithrombin where species-appropriate materials are available.

Testing Samples

Citrated Platelet-Poor Plasma

Sodium citrate anticoagulated plasma is the specimen of choice for functional antithrombin activity assays. Blood should be collected into 3.2% (0.109 mol/L) trisodium citrate tubes at a strict 9:1 blood-to-anticoagulant ratio. Platelet-poor plasma is prepared by double centrifugation (typically 1,500 × g for 15 minutes, repeated), and the plasma aliquot should be stored frozen at -70°C or below if analysis is delayed. Hemolyzed, clotted, or insufficiently filled specimens should be rejected, as they compromise result validity.

Species-Specific Specimens

Validated testing is available for a wide range of animal species, including canine, feline, equine, bovine, porcine, ovine, caprine, lapine, avian, and aquatic species. Because antithrombin concentration and reactivity differ substantially among species, assays must be validated for each target species using species-specific reference plasmas and reference intervals established from healthy population data. Cross-species use of human calibrators is scientifically unacceptable for quantitative reporting.

Research and Preclinical Specimens

For pharmacology and toxicology studies, plasma samples from laboratory animals (mice, rats, guinea pigs, rabbits, dogs, and non-human primates) are collected under controlled protocols, aliquoted, and shipped frozen on dry ice to prevent freeze-thaw cycles. Chain-of-custody documentation and stability data supporting the selected shipping condition are typically required by study sponsors and regulatory reviewers.

Animal-Dourced Biologic Products

Testing may also be applied to animal-derived or recombinant antithrombin concentrate products, where activity is assayed against pharmacopeial reference preparations to verify potency, batch consistency, and stability in accordance with pharmacopeial monograph requirements.

Testing Items

Core and supplementary test items offered under animal antithrombin activity evaluation include:

• Antithrombin activity (% relative to species-specific reference plasma), determined by functional amidolytic assay
• Antithrombin antigen concentration (mg/dL, g/L, or IU/mL), determined by immunological methods
• Heparin cofactor II activity, a complementary inhibitor evaluated in extended thrombophilia panels
• Thrombin-antithrombin (TAT) complex concentration, a marker of in vivo thrombin generation
• Coagulation profile companions: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, and D-dimer for integrated DIC assessment
• Functional-to-antigen ratio, used to distinguish qualitative (Type II-like) from quantitative (Type I-like) antithrombin deficiency

Testing Methods

Chromogenic Substrate (Amidolytic) Assay

The chromogenic assay is the reference method for functional antithrombin activity. Diluted patient plasma is incubated with an excess of purified thrombin or activated Factor Xa in the presence of a fixed concentration of heparin. Residual enzymatic activity, which is inversely proportional to the antithrombin activity in the specimen, cleaves a synthetic chromogenic substrate (typically a p-nitroaniline-conjugated peptide). Release of p-nitroaniline is measured spectrophotometrically at 405 nm, and activity is quantified against a multi-point calibration curve prepared from reference plasma dilutions. Anti-Xa-based assays are generally preferred in modern analyzers due to improved heparin tolerance and linearity.

Immunoturbidimetric and Nephelometric Assays

Antigen assays quantify the immunological mass of antithrombin protein using species-validated antibodies and latex-enhanced turbidimetry or immunonephelometry. These assays are rapid and highly precise, but they do not detect functional defects; therefore, antigen results should always be interpreted alongside functional activity measurements.

Enzyme-Linked Immunosorbent Assay (ELISA)

Sandwich ELISA provides high analytical sensitivity for antithrombin antigen and is well suited to research applications, low-volume species testing, and pharmacokinetic studies of antithrombin concentrates. Assay validation must document specificity, precision, accuracy, linearity, and reference interval verification for each matrix and species.

Clot-Based Assays

Older clotting-time-based methods measure the prolongation of thrombin time in the presence of heparin and test plasma. Although largely replaced by chromogenic platforms in modern practice, clot-based techniques remain useful in laboratories with limited instrumentation, provided method-specific validation is completed.

Quality Control and Standardization

Reliable testing requires species-specific validation, calibration against traceable reference materials, and participation in inter-laboratory comparison or proficiency testing where available. Laboratories operate under ISO/IEC 17025 quality systems, follow CLSI guidance on coagulation specimen collection, handling, and processing, and apply relevant national standards such as GB technical specifications where locally mandated. Known interferences, including therapeutic heparin, extreme lipemia, hemolysis, elevated bilirubin, and fibrin degradation products, must be evaluated and disclosed in method validation dossiers.

Applications

Animal antithrombin activity testing supports diverse clinical, regulatory, and research objectives:

• Veterinary clinical diagnostics: Identification of acquired antithrombin deficiency in DIC, chronic liver disease, nephrotic syndrome, protein-losing enteropathy, and sepsis in companion animals and livestock.
• Thrombosis risk stratification: Evaluation of hypercoagulable states in dogs with immune-mediated hemolytic anemia, hyperadrenocorticism, or pancreatitis, and in cats with hypertrophic cardiomyopathy and arterial thromboembolism risk.
• Heparin therapy management: Confirmation of adequate antithrombin status before and during unfractionated or low-molecular-weight heparin administration, and investigation of heparin resistance when activity falls below approximately 60%.
• Hereditary deficiency screening: Detection of familial quantitative or qualitative antithrombin defects in breeding populations and research colonies.
• Preclinical and regulatory studies: Safety pharmacology and toxicology assessment of anticoagulant, procoagulant, and endothelial-targeting investigational compounds in laboratory animal models.
• Biopharmaceutical quality control: Potency and stability testing of plasma-derived or recombinant antithrombin products using validated amidolytic assays traceable to pharmacopeial standards.

FAQ

What is the normal reference range for animal antithrombin activity?

Reference intervals vary by species, age, and analytical method. In most domestic mammals, functional activity commonly ranges from approximately 80% to 130% of species-specific pooled reference plasma. Each laboratory must establish and report its own validated reference intervals for the species and method in use.

Can a single assay be applied to all animal species?

No. Antithrombin concentration, heparin affinity, and cross-reactivity with reagent antibodies differ meaningfully among species. Quantitative reporting requires assay validation and calibration specific to each target species, and laboratories should be asked to confirm species coverage before sample submission.

How should samples be collected and shipped?

Collect blood into 3.2% sodium citrate at a 9:1 ratio, prepare platelet-poor plasma by centrifugation, aliquot into plastic tubes, freeze promptly at -70°C, and ship on dry ice with temperature monitoring. Repeated freeze-thaw cycles and ambient-temperature transport must be avoided.

Does ongoing heparin treatment interfere with testing?

Functional antithrombin assays are designed with excess heparin and are largely robust to therapeutic heparin levels; however, very high circulating heparin concentrations can bias some methods. disclosing the treatment history enables the laboratory to apply appropriate interpretation or pretreatment steps.

What is the difference between activity and antigen testing?

Activity testing measures the functional inhibitory capacity of antithrombin against thrombin or Factor Xa, whereas antigen testing measures the quantity of antithrombin protein regardless of function. A low activity result with normal antigen levels suggests a qualitative defect, while concordantly low results indicate quantitative deficiency.

What is a typical turnaround time?

Standard antithrombin activity determinations in accredited third-party laboratories are generally completed within three to seven working days after sample receipt, with expedited options available for urgent clinical or study-driven timelines.